Abstract
This statement sets out advice from the JCVI on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression around the time of their first or second vaccine doses.
Recommendation
Europe
United Kingdom
immunocompromised
COVID-19
